Patents Issued in November 9, 2004
  • Detergent
    Patent number: 6815404
    Abstract: The invention relates to a cleaning agent, particularly for cleaning sewers, for fat and/or protein-containing sewage from the home or having a municipal or industrial origin, with a content of urea, a urea derivative, a urea salt and/or a urea derivative salt, the cleaning agent containing approximately 50 to 90 wt. % urea, urea derivative, urea salt and/or urea derivative salt, based on dry substance, and an alkaline-acting agent, protease and fat-degrading microorganisms.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: November 9, 2004
    Assignee: BBT Bergedorfer Biotechnik GmbH
    Inventor: Klaus Becker
  • Liquid cleaning compositions containing an anionic surfactant mixture
    Patent number: 6815405
    Abstract: A cleaning composition with desirable cleansing properties to the human skin comprising at least one surfactant, a preservative system and water.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: November 9, 2004
    Assignee: Colgate-Palmolive Company
    Inventors: Julien Drapier, Francoise Siquet-Descans, Maria Galvez
  • Liquid dish cleaning compositions
    Patent number: 6815406
    Abstract: A liquid dish cleaning composition with desirable cleansing properties comprising two C8-18 ethoxylated alkyl ether sulfate surfactants, two anionic surfactant, an amine oxide surfactant, an acid and water.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: November 9, 2004
    Assignee: Colgate-Palmolive Company
    Inventor: Gregory Szewczyk
  • Vehicle cleaning fluid
    Patent number: 6815407
    Abstract: A composition by volume of 50% water, 42% hydrogen peroxide in a 3% solution and about 8% “Dawn” detergent when applied to insect residues spattered on vehicle surfaces is very effective in removing these residues. The composition is particularly efficient in removing Plecia nearctica, or “lovebug” debris from these surfaces in a manner that does not harm the vehicle finish, is inexpensive, environmentally acceptable and safe to handle.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: November 9, 2004
    Inventor: Rufus Sealey
  • Hydrogen peroxide stabilizer and resulting product and applications
    Patent number: 6815408
    Abstract: Hydrogen peroxide is stabilized by the addition of tri-potassium phosphate. This enhanced product is environmentally friendly and can be used in a variety of odor and disinfection applications without hazard to people, plants and things.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: November 9, 2004
    Inventor: Paul C. Wegner
  • Gel laundry detergent and/or pretreater which piles up after dispensing
    Patent number: 6815409
    Abstract: Gel detergent compositions which pile-up on a surface, upon dispensing, to minimize the spreading of the gel to a substantially larger area. The gels that can pile up are less messy to use and provide better stain removal, since more detergent is concentrated on the desired area of fabric (e.g., the spot). The composition comprises from about 10% to about 35% of a surfactant, from about 0.1 to about 5% of a non-neutralized fatty acid; from about 50 to about 85% of water; with the total of anionic surfactants selected from soap, linear alkyl benzene sulfonic acid, primary and secondary alkyl sulfates being more than 50% of total surfactant level.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: November 9, 2004
    Assignee: Unilever Home & Personal Care USA division of Conopco, Inc.
    Inventors: Feng-Lung Gordon Hsu, Yun-Peng Zhu, Ronald Frederick Vogel, Agnes Boudou, Charles Ebert, Kwang H Lee
  • Pouched cleaning compositions
    Patent number: 6815410
    Abstract: The present invention relates to a pouched cleaning composition wherein the pouch is constructed from a water-soluble film and contains a liquid composition comprising less than 5% by weight of the liquid composition, of water; an anionic surfactant; and at least 0.5% by weight of the liquid composition of a builder/chelant free of C8-22 alkyl or alkenyl chains characterized by a solubility in said liquid composition of less than 0.3% by weight. Such pouched cleaning compositions provide better cleaning performance and better pouch solubility while avoiding the formation of residues.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: November 9, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Jean-Pol Boutique, James Charles Theophile Roger Burckett-Saint-Laurent, Steven Jozef Louis Coosemans, Luca Goovaerts, Lorenzo Matteo Pierre Gualco, James Pyott Johnston
  • Fabric softening compositions and methods
    Patent number: 6815411
    Abstract: The present invention relates to stable, aqueous fabric softening compositions, fabric softening methods and articles of manufacture that use such fabric softening compositions comprising preferred polyalkyleneoxy polysiloxanes selected from the group consisting of polyethyleneoxy polysiloxane, polyethyleneoxy/polypropyleneoxy polysiloxanes, and mixtures thereof. The composition is preferably applied as small particle size droplets, especially from spray containers. The present invention also relates to a method of identifying, selecting, and/or designing the preferred polyethyleneoxy polysiloxanes and/or polyethyleneoxy/polypropyleneoxy polysiloxanes that provide superior fabric softening performance in general, and especially for use in the fabric softening composition of the present invention.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: November 9, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Toan Trinh, Eva Schneiderman, David Thomas Stanton, John William Smith, Michael Lee Kramer, Helen Bernardo Tordil, Gayle Marie Frankenbach, Zaiyou Liu, Mary Vijayarani Barnabas
  • Fabric softener compositions
    Patent number: 6815412
    Abstract: The present invention relates to a method of use of a softener composition for the antipilling treatment of textile fibre materials in domestic applications, which softener composition comprises: A) a fabric softener; B) at least on additive selected from the group consisting of a) a polyethylene, or a mixture thereof, b) a fatty acid alkanolamide, or a mixture thereof, c) a polysilicic acid, or a mixture thereof, and d) a polyurethane, or a mixture thereof; and C) a selected polyorganosiloxane compound.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: November 9, 2004
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Petr Kvita, Peter Otto, Mario Dubini, Harald Chrobaczek, Michael Geubtner, Ralf Goretzki, Barbara Weber, Emmanuel Martin
  • Macrocyclic ketones
    Patent number: 6815413
    Abstract: Lower alkyl- and lower alkylidene-substituted, saturated or unsaturated cyclohexadecanones are grand fragrances with muscone note with which perfumes with new odor notes can be prepared.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: November 9, 2004
    Assignee: Symrise GmbH & Co. KG
    Inventors: Marcus Eh, Ingo Wöhrle
  • Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
    Patent number: 6815414
    Abstract: The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: November 9, 2004
    Assignee: Vecta Ltd.
    Inventors: Michal Y. Chowers, Yehuda Chowers
  • Diagnosis and treatment of malignant neoplasms
    Patent number: 6815415
    Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 9, 2004
    Assignee: Rhode Island Hospital
    Inventors: Jack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
  • Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
    Patent number: 6815416
    Abstract: Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. Also disclosed is a method of stimulating the proliferation and expansion of chrondrocytes in vitro. The method comprises culturing chrondrocytes in the presence of a stimulating amount of an NPAR agonist.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: November 9, 2004
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Darrell H. Carney, Roger S. Crowther, Janet Stiernberg, John Bergmann
  • Method for treating obesity and for inhibiting adipocyte activity
    Patent number: 6815417
    Abstract: A method for treating obesity includes administering to humans or animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition. Stanniocalcin has an excellent activity of inhibiting the differentiation and maturation of adipocytes and therefore is useful as a drug for treating obesity.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: November 9, 2004
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Masaaki Goto, Akihiro Tomoyasu, Kyoji Yamaguchi, Masahiko Kinosaki, Nobuaki Nakagawa
  • TGF-&agr; polypeptides, functional fragments and methods of use therefor
    Patent number: 6815418
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 9, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Antiulcer agent
    Patent number: 6815419
    Abstract: The present invention provides antiulcer agents which can be orally administered while producing few side effects. These antiulcer agents contain &agr;-lactalbumin as an active ingredient, preferably in an amount of at least 0.5 mg/g.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: November 9, 2004
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Hirotoshi Hayasawa, Tomohiro Toida, Yukiko Shimokawa, Hiroshi Matsumoto
  • Methods of using chemokine beta-6
    Patent number: 6815420
    Abstract: Human chemokine &bgr;-6 agonist and antagonist polypeptides and DNA encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. The chemokine &bgr;-6 antagonists of the present invention may be employed to treat rheumatoid arthritis, lung inflammation, allergy, asmtha, infectious diseases and to prevent inflammation and atherosclerosis. The chemokine &bgr;-6 agonists may be employed to myeloprotect patients undergoing chemotherapy.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: November 9, 2004
    Assignee: Human Genome Sciences, INC
    Inventors: Brent L. Kreider, Steven M. Ruben, Henrik S Olsen
  • Polypeptides for use in ameliorating effects of aging in mammals
    Patent number: 6815421
    Abstract: Method of ameliorating effects of aging in an animal, the method comprising administering to the animal an effective amount of a synthetic polypeptide comprising an amino acid sequence that has 10+q amino acids, wherein, under physiological conditions, residues numbered n, n+4, n+9 are positively charged amino acids, residues numbered n+3, n+7 are negatively charged amino acids, wherein the remaining amino acids are nonpolar amino acids or uncharged polar amino acids, wherein n is an integer from 1 to 1+q and q is a whole number greater than or equal to zero. Experiments demonstrating the effect were performed with a polypeptide having the sequence Arg-Thr-Gln-Glu-His-Thr-Ala-Glu-Cys-Lys.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: November 9, 2004
    Assignee: Osteopharm Inc.
    Inventor: Cherk Shing Tam
  • Molecules with anti-inflammatory activity
    Patent number: 6815422
    Abstract: Here is described the use of angiostatin or its fragments to prepare a drug active against pathologies where is beneficial to obtain the inhibition of the migration, activation and release of active molecules from leucocyte of myeloid origin.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: November 9, 2004
    Assignee: Centro Biotechnologie Avanzate
    Inventors: Adriana Albini, Douglas Noonan, Roberto Benelli, Fabio Carrozzino, Leonardo Santi
  • Fluorescent substance P
    Patent number: 6815423
    Abstract: Light emitting compounds of the formula: wherein R1 is a light-emitting moiety and R2 is a substance P-based peptide, fragment, derivative or analog thereof, said peptide being linked at an amino acid position to (C—X), wherein (C—X) is selected from the group consisting of C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties, wherein said compound exhibits substantial biological activity in the presence of a receptor having affinity for substance P-based peptides.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: November 9, 2004
    Assignee: PerkinElmer LAS, Inc.
    Inventors: Clarissa Desjardins, Jacek Slon-Usakievicz, Alain Beaudet
  • Intranasal administration of polypeptides in powdered form
    Patent number: 6815424
    Abstract: Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: November 9, 2004
    Assignee: Pfizer Corporation
    Inventors: Brian H. Vickery, Eric J. Benjamin, Cherng-Chyi Fu, Lynda M. Sanders
  • Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
    Patent number: 6815425
    Abstract: A nueroprotectant composition wherein the active ingredient is pGLU-GLU-PRO-NH2 or a combination of pGLU-GLU-PRO-NH2 (EEP) and N-tert-Butyl-&agr;-(2-sulfophenyl)nitrone (SPBN) or other nitrone. A method of treating and preventing diseases and injuries of the brain, spinal cord and retina is also presented by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 9, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: James L. Meyerhoff, Michael L. Koenig, Joseph B. Long
  • Angiogenesis-inhibitory tripeptides, compositions and their methods of use
    Patent number: 6815426
    Abstract: This invention pertains to methods and compositions for inhibiting endothelial cell tube formation, the initial step of tumor angiogenesis. More specifically, the present invention relates to tripeptides that show inhibition of angiogenesis-mediated processes.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: November 9, 2004
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Mark A. Scialdone, Shaker Ahmed Mousa, Steven W. Shuey
  • Sericin-containing material, process for producing the same method of using the same
    Patent number: 6815427
    Abstract: The object of the present invention is to elucidate a biologically active function of a component constituting undegraded sericin and to provide a novel medical material, cosmetic material, etc. utilizing the functional composition. Disclosed is a cell growth promoter obtainable by elution from a fiber discharged by a domestic silkworm, e.g., cocoon filaments or the like, wherein the cell growth promoter comprises sericin having a molecular weight of about 400,000 as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as a main component. This cell growth promoting agent (substance) is extremely useful because growth of cells is promoted when it is used in a wound dressing material, a vascular endothelium forming material and an organ forming material for medical use, in a cell culture base material for biological use, or in a cosmetic material for skin care use.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: November 9, 2004
    Assignee: National Institute of Agrobiological Sciences
    Inventors: Kozo Tsubouchi, Hiromi Yamada, Yoko Takasu
  • Pyrazole derivatives and diabetic medicine containing them
    Patent number: 6815428
    Abstract: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: November 9, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Koji Ohsumi, Takashi Umemura, Hiroyuki Matsueda, Toshihiro Hatanaka, Akiko Onuki, Katsumi Maezono, Yoko Kageyama, Nobuo Kondo
  • Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
    Patent number: 6815429
    Abstract: The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: November 9, 2004
    Assignee: Hybridon, Inc.
    Inventor: Sudhir Agrawal
  • Gene expression base sequences for therapeutic use and drugs for gene therapy
    Patent number: 6815430
    Abstract: The base sequence for the expression of a therapeutic gene and the medicament for gene therapy are disclosed. There is also disclosed the base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. Moreover, there is disclosed the medicament for gene therapy containing a therapeutic gene downstream any of the above-mentioned base sequences, capable of directing the expression of the therapeutic gene specifically to squamous epithelium.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: November 9, 2004
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Kazuhiro Yuda, Katsuhiko Akiyama, Takeshi Goto, Katsuyuki Hamada
  • Methods for therapy of neurodegenerative disease of the brain
    Patent number: 6815431
    Abstract: A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by directly delivering a definite concentration of recombinant neurotrophin, into a targeted region of the brain using an expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: November 9, 2004
    Assignee: Regents of the University of California
    Inventor: Mark H. Tuszynski
  • Methods for encapsulating plasmids in lipid bilayers
    Patent number: 6815432
    Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: November 9, 2004
    Assignee: Inex Pharmaceuticals Corp.
    Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
  • Composition and method for the treatment of dysglucaemia
    Patent number: 6815433
    Abstract: Dysglucaemia is treated and/or prevented by the administration of granulated starch, enzymatically degraded and releasing reducing sugars at a rate, adjusted to the metabolism of the patient, suffering from dysglucaemia. For example nocturnal hypoglycaemia in diabetic patients is prevented by administering to said patients a granulate or tablets comprising granulated cornstarch, and preferably also heat treated cornstarch and a low calorie sweetener. The inventive granulation minimizes the available surface area and retards the enzymatic degradation of the cornstarch and ensures a controlled, e.g. a substantially linear release of reducing sugars, such as glucose, and a stable blood glucose level during several hours. The granulate or tablets are low in calories and contain no free sugar.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: November 9, 2004
    Assignee: Metcon Medicin AB
    Inventors: Henri Hansson, Mats Lake, Kerstin Hansson
  • Methods for treating hearing loss
    Patent number: 6815434
    Abstract: In one aspect, the present invention provides otoprotectant compositions useful for ameliorating hearing loss. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic and at least one otoprotectant selected from the group consisting of a xanthine oxidase inhibitor and a glutathione or glutathione precursor. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic, at least one xanthine oxidase inhibitor, at least one glutathione or glutathione precursor. In another aspect, the present invention provides methods for ameliorating hearing loss by administering to a subject an amount of an otoprotective composition that is effective to ameliorate hearing loss.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: November 9, 2004
    Assignee: Sound Pharmaceuticals Incorporated
    Inventors: Jonathan Kil, Eric D. Lynch
  • Pharmaceutical compositions containing DDS compounds
    Patent number: 6815435
    Abstract: A pharmaceutical composition having an ensured preservation stability, which contains a compound, wherein a polysaccharide derivative having a carboxyl group is bonded to a camptothecin derivative via a spacer or without mediated by any spacer, and a sugar or a sugar alcohol optionally together with a pH-adjusting substance.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: November 9, 2004
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Masayuki Takahashi, Shuichi Sugie, Masahito Takeuchi
  • Composition and method for the treatment of dysglucaemia
    Patent number: 6815436
    Abstract: Dysglucaemia is treated and/or prevented by the administration of granulated starch, enzymatically degraded and releasing reducing sugars at a rate, adjusted to the metabolism of the patient, suffering from dysglucaemia. For example nocturnal hypoglycaemia in diabetic patients is prevented by administering to said patients a granulate or tablets comprising granulated cornstarch, and preferably also heat treated cornstarch and a low calorie sweetener. The inventive granulation minimises the available surface area and retards the enzymatic degradation of the cornstarch and ensures a controlled, e.g. a substantially linear release of reducing sugars, such as glucose, and a stable blood glucose level during several hours. The granulate or tablets are low in calories and contain no free sugar.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: November 9, 2004
    Assignee: Metcon Medicin AB
    Inventors: Henri Hansson, Mats Lake, Kerstin Hansson
  • Streptogramines, their preparation and compositions containing them
    Patent number: 6815437
    Abstract: Group A streptogramin derivatives of formula (I): the salts thereof, and mixtures of stereoisomers thereof, as well as processes for preparing them and pharmaceutical compositions comprising them are disclosed.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: November 9, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Alain Commerçon, Hervé Bouchard, Yves Ribeill, Eric Bacque, Baptiste Ronan, Jean-Claude Barriere, Gérard Puchault, Corinne Terrier
  • Heteroaryl-diazabicycloalkanes
    Patent number: 6815438
    Abstract: The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: November 9, 2004
    Assignee: Neurosearch A/S
    Inventors: Dan Peters, Gunnar M. Olsen, Elsebet Ostergaard Nielsen, Philip K. Ahring, Simon Feldbaek Nielsen, Tino Dyhring Jorgensen
  • Substituted aza-oxindole derivatives
    Patent number: 6815439
    Abstract: Substituted aza-oxindole derivatives useful as cyclin dependent kinase II inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: November 9, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Philip Anthony Harris, Lee Frederick Kuyper, Karen Elizabeth Lackey, James Marvin Veal
  • Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
    Patent number: 6815440
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: November 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Reaction products of taurultam and glucose
    Patent number: 6815441
    Abstract: Reaction products of taurultam and glucose are useful as antineoplastic agents. They are produced by reacting an aqueous solution of taurultam and glucose at about 100 degrees Celsius for about 30 minutes, yielding a reaction product which has a melting point of 168 to 170 degrees Celsius.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: November 9, 2004
    Assignee: Ed. Geistlich Soehne AG fuer chemische Industrie
    Inventors: Ruediger Stendel, Rolf W. Pfirrmann
  • Quinoxalinones for enhancing chemotherapy
    Patent number: 6815442
    Abstract: The present invention provides 1H-quinoxalinones, of the formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, and n are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: November 9, 2004
    Assignee: The Penn State Research Foundation
    Inventors: Charles D. Smith, David S. Lawrence
  • 5-Amino-1-pentene-3-ol substituted derivatives
    Patent number: 6815443
    Abstract: The invention relates to 5-amino-1-pentene-3-ol substituted derivatives, a method for the production thereof, medicaments containing said compounds, the use of substituted 5-amino-1-pentene-3-ol derivatives for the production of medicaments, and methods of treatment using the medicaments.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: November 9, 2004
    Assignee: Gruenenthal GmbH
    Inventors: Helmut Buschmann, Corinna Maul, Bernd Sundermann, Utz-Peter Jagusch, Michael Haurand, Boris Chizh
  • Anti-enterovirus compounds
    Patent number: 6815444
    Abstract: This invention features, among others, a pyrazolopyrimidine compound of formula (A): A is (CH2)q—CHRaRb; each of R1 and R2, independently, is hydrogen, halogen, cyano, nitro, or alkyl; or R1 and R2 taken together is (CH2)r; each of R3 and R4, independently, is hydrogen, halogen, cyano, nitro, or alkyl; each of R5, Ra, and Rb, independently, is aryl, aralkyl, or heteroaryl, optionally substituted with halogen, cyano, nitro, alkyl, aryl, aralkyl, heteroaryl, OR, O(O)CR, C(O)R, C(O)OR, C(O)NRR′, SR, S(O)R, S(O)OR, NRR′, NR(O)CR′, NRC(O)OR′, or NRC(O)NR′R″; each of m, n, o, p, and r, independently, is 0 or 1, and q is 0, 1, or 2; in which each of R, R′, and R″, independently, is hydrogen or alkyl, provided that the sum of m, n, o, and p is 1, 2, 3, or 4.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: November 9, 2004
    Assignee: National Health Research Institutes
    Inventors: Jyh-Haur Chern, Kak-Shan Shia, Shin-Ru Shih, Tsu-An Hsu, Chia-Liang Tai
  • Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
    Patent number: 6815445
    Abstract: The present invention is directed to a compound of Formula I: wherein A, R1, and R2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: November 9, 2004
    Inventors: Theodore E. Carver, Jr., James M. Rinker
  • Selective antagonists of A2B adenosine receptors
    Patent number: 6815446
    Abstract: A compound of the following formula: wherein R is an aliphatic or cycloaliphatic amine group or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable salt thereof. The compounds of formula (I) may be used to treat, among other indications, asthma and diarrhea.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: November 9, 2004
    Assignee: Vanderbilt University
    Inventors: Italo O. Biaggioni, Igor A. Feoktistov, Jack N. Wells
  • N-type calcium channel antagonists for the treatment of pain
    Patent number: 6815447
    Abstract: Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2 and R3 are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: November 9, 2004
    Assignee: Astrazeneca AB
    Inventors: Bipinchandra Chaudhari, Marc Chapdelaine, Greg Hostetler, Lucius Kemp, John McCauley
  • Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
    Patent number: 6815448
    Abstract: Compounds of the formula are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia. The compounds of the invention are also useful for the treatment of disorders such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: November 9, 2004
    Assignee: Wyeth
    Inventors: Gary P. Stack, Megan Tran
  • LK6-A derivatives
    Patent number: 6815449
    Abstract: Compounds having immunosuppressive activity, cell growth inhibitory activity, anti-tumor activity, etc. are represented by formula I: and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: November 9, 2004
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Tsutomu Akama, Hiroyuki Nagata, Atsuhiro Hasegawa, Harumi Ue, Isami Takahashi, Yutaka Saitoh, Kenichi Mochida, Shun-ichi Ikeda, Yutaka Kanda
  • Axon regeneration with PKC inhibitors
    Patent number: 6815450
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: November 9, 2004
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
    Patent number: 6815451
    Abstract: The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists especially urotensin II antagonists.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: November 9, 2004
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Jörg Velker, Hamed Aissaoui, Christoph Binkert, Martine Clozel, Boris Mathys, Claus Mueller, Oliver Nayler, Michael Scherz, Thomas Weller
  • Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
    Patent number: 6815452
    Abstract: Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: November 9, 2004
    Assignee: Boehringer Ingelheim Pharma KG & Co GmbH
    Inventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhaeuser, Sabine Pestel, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Cosmetic and dermatological light protection formulations having a content of triazine derivatives and glyceryl compounds
    Patent number: 6815453
    Abstract: Active compound combinations, which have a light protection action, of 4,4′,4″-(1,3,5-triazine-2,4,6-triyltriimino)-trisbenzoic acid tris(2-ethylhexyl ester) and one or more emulsifiers chosen from the group of substances of the general structural formula wherein R1, R2 and R3 independently of one another are chosen from the group which comprises: H and branched and unbranched, saturated and unsaturated fatty acid radicals having 8 to 24 carbon atoms, in which up to three aliphatic hydrogen atoms can be replaced by hydroxyl groups, and n is a number from 2 to 8.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: November 9, 2004
    Assignee: Beiersdorf AG
    Inventors: Heinrich Gers-Barlag, Rainer Kröpke, Anja Müller